Business Context and Reporting Period
This Form 8-K reports on the results of the 2022 Annual Meeting of Stockholders held by Aquestive Therapeutics, Inc. on June 22, 2022. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Director Election: Daniel Barber was elected as a Class I member of the Board of Directors for a three-year term ending at the 2025 Annual Meeting.
- Votes For: 16,791,712
- Votes Against: 0
- Votes Abstaining: 296,348
- Broker Non-Votes: 12,665,836
- Auditor Ratification: The appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, was ratified.
- Votes For: 29,240,450
- Votes Against: 359,333
- Votes Abstaining: 154,113
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of Daniel Barber's tenure on the Board of Directors through 2025.
- Verification of KPMG LLP's role as the independent auditor for the 2022 fiscal year.
- Review of the significant number of broker non-votes (12,665,836) regarding the director election.